Lead Pharma Holding BV, of Oss, the Netherlands, triggered the fourth milestone under its agreement with Paris-based Sanofi SA with the start of dosing in a phase I study of SAR-441169, an inverse agonist of nuclear hormone receptor RORyt, in healthy volunteers.